Kidney Failure
201
20
30
110
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
32 trials with published results (16%)
Research Maturity
110 completed trials (55% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
11.4%
23 terminated out of 201 trials
82.7%
-3.9% vs benchmark
27%
54 trials in Phase 3/4
29%
32 of 110 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 110 completed trials
Clinical Trials (201)
Delayed Tolerance Through Mixed Chimerism
Tolerance Through Mixed Chimerism (Sip-Tego)
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
Tenofovir Exposures in Advanced Kidney Disease Study
Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin
Predictors of Rapid CKD Progression
Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department
Comprehensive Kidney Function Assessment and Early Warning in Older Adults
Does Incremental Initiation of Haemodialysis Preserve Native Kidney Function?
The Effect of Virtual Reality Glasses Applied to Hemodialysis Patients on Vital Signs and Anxiety Level
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Epidemiology of Complications After Solid Organ Transplantation - EpCOT Study
STarting incrEmental Prescription of Peritoneal Dialysis
Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients